{
  "extraction_metadata": {
    "timestamp": "2025-10-02T14:33:35.911479",
    "source_type": "hta_submission",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "total_countries": 11,
    "temperature": 0.1
  },
  "outcomes_by_country": {
    "AT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "AT",
      "Outcomes": "all-cause mortality, overall survival (OS), tumor response rate, adverse events, quality of life, liver function, tumor reduction, time to progression (TTP), disease control rate (DCR), time to symptomatic progression (TTSP), mRECIST response, complication incidence, mortality, disease recurrence, length of hospital stay, complications, fatigue (EORTC QLQ-HCC18), pain (EORTC QLQ-HCC18), jaundice (EORTC QLQ-HCC18), fever (EORTC QLQ-HCC18), abdominal swelling (EORTC QLQ-HCC18), liver failure, post-treatment complications, EORTC QLQ-C30, EORTC QLQ-HCC18, European Quality of Life – 5 Dimensions Visual Analogue Scale (EQ-5D VAS), health status, health-related quality of life, global health status, function scales of EORTC QLQ-C30, function scales of EORTC QLQ-HCC18",
      "ChunksUsed": 10,
      "ContextTokens": 1974
    },
    "CZ": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "CZ",
      "Outcomes": "",
      "ChunksUsed": 1,
      "ContextTokens": 202
    },
    "DE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DE",
      "Outcomes": "all-cause mortality, overall survival (OS), tumor response rate, adverse events, quality of life, liver function, tumor reduction, time to progression (TTP), time to symptomatic progression (TTSP), disease control rate (DCR), hand-foot skin reaction, diarrhoea, hypertension, skin rash, desquamation, hypody, pain (EORTC QLQ-HCC18), jaundice (EORTC QLQ-HCC18), fever (EORTC QLQ-HCC18), abdominal swelling (EORTC QLQ-HCC18), fatigue (EORTC QLQ-HCC18), EORTC QLQ-C30, EORTC QLQ-HCC18, European Quality of Life – 5 Dimensions Visual Analogue Scale (EQ-5D VAS), health status, disease recurrence, length of hospital stay, complications",
      "ChunksUsed": 10,
      "ContextTokens": 2102
    },
    "DK": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DK",
      "Outcomes": "overall survival (OS), progression-free survival (PFS), progression-free survival (PFS; RECIST 1.1), time to progression (TTP), objective response rate (ORR), complete response (CR), partial response (PR), tumour response rate, time to response, duration of response (DoR), disease control rate (DCR; mRECIST), clinical benefit rate (CBR), plasma pharmacokinetics lenvatinib exposure parameters, adverse events (general), serious adverse events, adverse events leading to discontinuation, treatment-emergent adverse events (TEAE), diarrhoea, nutrition, pain, body image, EORTC QLQ-C30, EORTC QLQ-HCC18, EQ-5D, health-related quality of life (HRQoL), time to clinically meaningful worsening of EQ-5D, time to clinically meaningful deterioration of EORTC QLQ-C30 domains, time to clinically meaningful deterioration of EORTC QLQ-HCC18 domains, quality-adjusted life years (QALYs), cost-effectiveness (incremental cost-effectiveness ratio, ICER), blood and tumour biomarkers correlated with clinical outcomes",
      "ChunksUsed": 10,
      "ContextTokens": 2243
    },
    "EN": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "EN",
      "Outcomes": "overall survival, progression-free survival, health-related quality of life, adverse events, cost-effectiveness (incremental cost-effectiveness ratio, ICER), quality-adjusted life years (QALYs)",
      "ChunksUsed": 10,
      "ContextTokens": 1788
    },
    "ES": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "ES",
      "Outcomes": "overall survival (OS; time from randomisation to death from any cause), progression-free survival (PFS; time from randomisation to tumour progression defined by RECIST 1.1 or death from any cause), objective response rate (ORR; percentage of patients with partial or complete response; RECIST 1.1), objective response rate (ORR; percentage of patients with partial or complete response; mRECIST), duration of response (DoR; time from partial or complete response to disease progression or exit), deterioration in patient quality of life (EORTC QLQ-C30), deterioration in patient quality of life (EORTC QLQ-HCC18), time to patient-reported impairment of quality of life (EORTC QLQ-C30), time to patient-reported impairment of quality of life (EORTC QLQ-C30 functional role subscale), time to patient-reported impairment of quality of life (EORTC QLQ-C30 fitness subscale), serious adverse events, grade 5 adverse events, drug withdrawal due to adverse events, dose modification due to adverse events",
      "ChunksUsed": 10,
      "ContextTokens": 3097
    },
    "FR": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "FR",
      "Outcomes": "overall survival (OS; time from randomization to death from any cause), progression-free survival (PFS; time from randomization to disease progression or death), time to progression (TTP; time from randomization to disease progression), objective response rate (ORR), disease control rate, clinical benefit rate, hepatotoxicity, hypertension, loss of appetite, weight loss, haemorrhagic events, thromboembolic events, hypothyroidism, serious adverse events, grade 3 adverse reactions, treatment-related deaths, adverse events (general), EQ5D-3L",
      "ChunksUsed": 10,
      "ContextTokens": 2372
    },
    "NL": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "NL",
      "Outcomes": "overall survival, time to symptom progression, time to progression, disease control, partial response, minor response (reduction of tumour size by 25 to 50%), stable disease (for at least 16 weeks), fatigue, bleeding, abdominal pain, hypertension, diarrhoea, lymphoedema, hand feeding reactions, serious adverse reactions (grade 3/4), adverse reactions",
      "ChunksUsed": 10,
      "ContextTokens": 1717
    },
    "PO": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "PO",
      "Outcomes": "overall survival (OS), progression-free survival (PFS), time to progression (TTP), objective response rate (ORR), complete response (CR), partial response (PR), stable disease (SD), disease control rate (DCR), number needed to harm (NNH), number needed to treat (NNT), hazard ratio (HR), mean difference (MD), relative risk (RR), risk difference (RD), hand-foot skin reaction, diarrhoea, rash, skin desquamation, fatigue, weight loss, hypertension, decreased appetite, hypocalcaemia, increased ALT activity, secondary cancer, dyspnoea, pleural effusion, alopecia, cough, back pain, limb pain, adverse events (general), FACT-G (Functional Assessment of Cancer Therapy – General), EQ-5D (Euro QoL – 5 dimensions), EQ VAS (Euro QoL visual analogue scale)",
      "ChunksUsed": 10,
      "ContextTokens": 2580
    },
    "PT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "PT",
      "Outcomes": "overall survival (OS), progression-free survival (PFS), progression-free survival (modified RECIST), time to progression (TTP), objective response rate (ORR), quality of life, EORTC QLQ-C30, EORTC QLQ-HCC18, pharmacokinetic parameters, vital signs, laboratory haematological testing, laboratory biochemical testing, urinalysis, electrocardiography, adverse events (graded by National Cancer Institute), grade 3 adverse events, grade 4 adverse events, fatal adverse events, tumour haemorrhage, ischaemic stroke, respiratory failure, sudden death, treatment-related mortality",
      "ChunksUsed": 10,
      "ContextTokens": 2163
    },
    "SE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "SE",
      "Outcomes": "overall survival (OS; time from randomization to death from any cause), progression-free survival (PFS), objective tumour response, time to tumour progression, quality of life weights, adverse reactions of grade 3 or higher, Eastern Cooperative Oncology Group Performance Status (ECOG PS), tumour spread (TNM system), liver function (Child-Pugh scale), cost-benefit analysis",
      "ChunksUsed": 10,
      "ContextTokens": 1844
    }
  }
}